

IFW



Appl. No : 10/560,103 Confirmation No.: Unknown  
Applicant : Kelly M. McNagny et al.  
Filed : June 9, 2004  
Title : Methods for Detecting and Treating Cancer Using  
Podocalyxin and/or Endoglycan  
TC./A.U. : Unknown  
Examiner : Unknown  
  
Docket No. : 7685-102  
Customer No. : 001059

Honorable Commissioner for Patents  
P. O. Box 1450  
Alexandria, Virginia 22313-1450

### **FILING OF AN INFORMATION DISCLOSURE STATEMENT**

In accordance with 37 CFR 1.97 and 1.98, and in recognition of the duty of disclosure set forth in 37 CFR 1.56, Applicant hereby submits an Information Disclosure Statement on Form PTO-1449 containing a listing of publications of which Applicant is aware. Applicant is also submitting the references listed on the Information Disclosure Statement.

All of the patents and publications submitted herewith are in the English language. Accordingly a concise explanation of the relevance of the documents is not required.

The Examiner is requested to indicate consideration of these documents by initialing the appropriate column.

Applicants reserve the right to contest the applicability of any of these documents as prior art against the subject application. If the Examiner has any questions concerning this Information Disclosure Statement, he/she is requested to contact the undersigned. Entry of the enclosed Information Disclosure Statement is believed to be in order and is respectfully requested.

This Information Disclosure Statement is being filed before the issuance of a first official action, and therefore no fees are required. However, please charge our deposit account No. 02-2095 if such a fee is required.

Respectfully submitted,

**Kelly M. McNagny et al.**

A handwritten signature in black ink, appearing to read "M. Gravelle".


Micheline Gravelle  
Registration No. 40,261

Dated: March 10, 2006

Bereskin & Parr  
Box 401, 40 King Street West  
Toronto, Ontario, Canada  
M5H 3Y2

(416) 364-7311

PTO/SB/08a (08-03)



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	Unknown
Filing Date	Unknown
First Named Inventor	Kelly M. McNagny
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	7685-102

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	SCHOPPERLE, W.M. et al., Human Embryonal Carcinoma Tumor Antigen, Gp200/GCTM-2, is podocalyxin, Biochem. Biophys. Res. Comm., vol. 300, no. 2, January 10, 2003, pages 285-290.	
	2	FIEGER, C.B. et al., Endoglycan, A member of the CD34 family, functions as an L-selectin ligand through modification with tyrosine sulfation and sialyl Lewis x., J. Biol. Chem., vol. 278, no. 30, May 16, 2003.	
	3	SOMASIRI, A. et al., Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression, Cancer Res., vol. 64, August 1, 2004, pages 5068-5073.	
	4		
	5		
	6		
	7		
	8		
	9		
	10		
	11		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.